About Cizzle Bio, Inc.
Transforming Lung Cancer Detection through Pioneering Science
Who We Are
Cizzle Bio, Inc. stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.
Meet the Team
Bill Behnke
CHAIRMAN & CEO
Dr. Ron Greeno
SENIOR ADVISOR
Dr. Ajay Goel
SCIENTIFIC ADVISOR
Dr. Steven T. Rosen
SCIENTIFIC ADVISOR
Dr. William Dalton
SCIENTIFIC ADVISOR
Mary Jimenez
EXECUTIVE VICE PRESIDENT OF BUSINESS DEVELOPMENT
Derek Schriver
EXTERNAL FINANCIAL OFFICER
Daniela Kuok
COMMUNICATIONS & MARKETING COORDINATOR
Sai
DIRECTOR OF WEB & IT
Meet our Board of Directors
Bill Behnke
BOARD CHAIRMAN
Dr. Ron Greeno
BOARD MEMBER
Joseph Kelley
BOARD MEMBER
Our Journey and Technology
Born from a partnership with Cizzle Biotechnology PLC, we utilize patented technologies that have set new standards in the early detection of lung cancer. Our research and development efforts have culminated in proprietary monoclonal antibodies specific to CIZ1B, paving the way for the development of our first market-ready tests.
Leadership in Innovation
Under the leadership of Dr. Allan Syms and Professor Dawn Coverley, our team combines decades of expertise in cancer biology and cell biology, respectively. This blend of skills ensures that Cizzle Bio remains at the cutting edge of cancer diagnostics, driving innovations that promise better survival rates for patients worldwide.
The Critical Need for Early Detection
The majority of lung cancer cases are diagnosed too late, with devastating consequences. Our mission is to change this narrative by providing a reliable, non-invasive, and easily accessible testing option that can dramatically improve survival rates.
Strategic Partnership for Greater Impact
Guided by Bill Behnke, a veteran healthcare executive, we actively cultivate strategic partnerships across the healthcare spectrum—from cancer centers to insurance companies. These relationships enhance the reach and effectiveness of our diagnostic solutions, ensuring they benefit a wide and diverse patient population.
Innovation at Our Core
Our commitment extends beyond traditional methods. We are developing point-of-care tests that could be as routine as checking your blood pressure, making early detection a regular part of medical care.
Learn more about the CIZ1 B Biomarker.
Educating and Empowering Communities
At Cizzle Bio, we believe in empowering individuals to take proactive steps towards managing their health. Through educational initiatives and community outreach, we raise awareness about the benefits of early lung cancer detection and encourage widespread participation in screening programs.
Our Vision for the Future
Our vision is clear: a future where lung cancer is detected early enough to be treated effectively, drastically reducing late-stage diagnoses and mortality rates. Every innovation, every partnership, and every test we develop is a step towards this future.